What is he best known for?
The fields of study he is best known for:
Helder I. Nakaya focuses on Immunology, Virology, Immunity, Antibody and Vaccination.
His Immunology study typically links adjacent topics like Cytotoxic T cell.
His studies deal with areas such as Intestinal mucosa, Antigen-presenting cell, Inflammation, Immune tolerance and Regulatory T cell as well as Immunity.
His work deals with themes such as Virus, Influenza A virus and Innate immune system, which intersect with Antibody.
His Influenza A virus research incorporates themes from Germinal center, Antigen and TLR4.
Helder I. Nakaya interconnects Antibody titer and Immunogenicity in the investigation of issues within Vaccination.
His most cited work include:
- Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans (818 citations)
- Programming the magnitude and persistence of antibody responses with innate immunity. (703 citations)
- Programming the magnitude and persistence of antibody responses with innate immunity. (703 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Immunology, Immune system, Virology, Immunity and Vaccination.
His study in Transcriptome extends to Immunology with its themes.
His Immune system study integrates concerns from other disciplines, such as Cytokine and Cell biology.
His Virology study combines topics in areas such as Polyarthritis, Antibody and Monocyte.
The concepts of his Antibody study are interwoven with issues in Influenza A virus and Antigen.
His study in Immunity is interdisciplinary in nature, drawing from both Antibody titer, Live attenuated influenza vaccine, Systems biology and Malaria.
He most often published in these fields:
- Immunology (61.11%)
- Immune system (37.22%)
- Virology (25.00%)
What were the highlights of his more recent work (between 2019-2021)?
- Immunology (61.11%)
- Immune system (37.22%)
- Severe acute respiratory syndrome coronavirus 2 (3.89%)
In recent papers he was focusing on the following fields of study:
Helder I. Nakaya mostly deals with Immunology, Immune system, Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019 and Inflammation.
His Immunology research includes elements of Pandemic, Lung and Coronavirus.
His research integrates issues of Epitope, Cytokine storm, Cell type and Vaccination in his study of Immune system.
His Vaccination research is multidisciplinary, relying on both Antibody, Ebolavirus and Immunity.
His Immunity research focuses on Immunogenicity and how it relates to Omics data.
His work investigates the relationship between RNA virus and topics such as Virology that intersect with problems in Real-time polymerase chain reaction.
Between 2019 and 2021, his most popular works were:
- Evolution and epidemic spread of SARS-CoV-2 in Brazil. (157 citations)
- Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis (122 citations)
- ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19. (116 citations)
In his most recent research, the most cited papers focused on:
Helder I. Nakaya spends much of his time researching Immunology, Transmission, Severe acute respiratory syndrome coronavirus 2, Geography and Coronavirus disease 2019.
His biological study focuses on Immune system.
He has included themes like Inflammation, Lymphocytopenia, Signal transduction and Mitochondrion in his Immune system study.
His Severe acute respiratory syndrome coronavirus 2 research includes themes of Hypoxia, Cell stress and Enzyme.
His study in Coronavirus disease 2019 is interdisciplinary in nature, drawing from both Esophagus, Receptor, Viral load and Outbreak.
His Coronavirus research is multidisciplinary, incorporating elements of Antibody-dependent enhancement, Pneumonia, CD8, Bronchoalveolar lavage and Programmed cell death.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
